准SKP2以对抗多发性骨髓瘤中耐药性的治疗
Omar Faruq1,2, Jane Ngo1,2, Deepak Iyer1,2
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, M5S 1A8, Canada.
Scientific reports
|October 30, 2025
概括
用SkpinC1针对SKP2显示出克服多发性骨髓瘤 (MM) 耐药性的希望. 这种抑制减少了关键的信号通路,并提高了对博尔特佐米布等现有疗法的敏感性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 多发性骨髓瘤 (MM) 是一种不可治愈的血细胞癌,具有显著的治疗药物耐药性.
- SKP2是SCF-SKP2泛基因-蛋白质结合酶复合体的关键组成部分,与MM的癌症进展和药物耐药性有关.
研究的目的:
- 调查SKP2在多发性骨髓瘤进展和耐药性的作用.
- 评估在MM中使用临床前抑制剂SkpinC1抑制SKP2的治疗潜力.
主要方法:
- 对多发性骨髓瘤不同阶段SKP2表达的分析.
- 利用基因组丰富分析 (GSEA) 和免疫包裹来评估SkpinC1.1.的影响.
- 在SKP2-过度表达MM细胞和患者衍生的样本中测试SkpinC1.
主要成果:
- 在MM中,发现SKP2表达随着疾病进展而增加.
- SkpinC1治疗导致MM细胞中的STAT3信号和c-MYC表达减少.
- SkpinC1降低了激活的STAT3,c-MYC和c-MAF水平,损害了细胞生长并诱导了细胞亡.
- 在患者骨髓瘤样本中,SkpinC1协同增强了博尔特佐米布的疗效.
结论:
- SKP2抑制是克服多发性骨髓瘤耐药性的有希望的策略.
- 准SKP2可能会恢复对传统疗法的敏感性,并为MM患者提供新的治疗途径.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


